In a recent interview at the SNMMI conference, Dr. Krishna Patel discussed the benefits of the PET perfusion radiotracer agent 18F-flurpiridaz in diagnosing coronary artery disease (CAD) in obese patients. Conventional imaging methods such as SPECT and CCTA can be challenging for obese patients due to attenuation artifacts and lack of image quality. Dr. Patel and colleagues conducted a study comparing 18F-flurpiridaz with 99mTc-SPECT in 298 obese patients and found that 18F-flurpiridaz demonstrated higher sensitivity and specificity rates in detecting CAD. The use of 18F-flurpiridaz also reduced radiation exposure compared to other modalities. Other benefits of 18F-flurpiridaz include a longer half-life and availability of unit dose, which may improve access to stress cardiac PET myocardial perfusion imaging.
Fri, 07 Jul 2023 12:04:48 GMT | Diagnostic Imaging